Clinical TrialCompleted

Imperial College London Open-Label Psilocybin Pilot for Treatment-Resistant Depression (Carhart-Harris / Lyons 2016–2018)

Open-label, uncontrolled pilot study of oral psilocybin for treatment-resistant depression at Imperial College London (Front Psychol 2018; Lyons T, Carhart-Harris RL; PMID 30369890; DOI 10.3389/fpsyg.2018.01721; also reported: Carhart-Harris et al. Lancet Psychiatry 2016 n=12, Neuropharmacology 2018 n=20). n=15 TRD patients + 15 healthy controls matched on age/gender/education. Patients: clinically assessed TRD. Intervention: oral psilocybin 10 mg (safety dose) one week before oral psilocybin 25 mg (treatment dose); unblinded, open-label. Outcomes in this paper: future-event forecasting (optimism bias test) at baseline and 1 week post-25 mg session; QIDS-SR depression at baseline and 1 week. Neither patients nor research team masked to treatment. UK regulatory/ethics approval obtained. No CT.gov registration found (searches by PMID, Carhart-Harris, and TRD+psilocybin+UK). Possible ISRCTN or NHS HRA registration not confirmed from available metadata.

Target Enrollment
20 participants
Study Type
interventional
Design
Non-randomized

Study Details

  • Status
    Completed
  • Type
    interventional
  • Design
    Non-randomized
  • Target Enrollment20 participants
  • Timeline
    Start: 2015-01-01
    End: 2016-12-31

Related Publications

Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Published
Authors
Watts, R., Day, C. M., Krzanowski, J., Nutt, D. J., Carhart-Harris, R. L.

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Published
Authors
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, N., Wall, M. B., Tanner, M., Kaelen, M., Mcgonigle, J., Murphy, K., Leech, R., Curran, V., Nutt, D. J.

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression

Published
Authors
Stroud, J., Freeman, T. P., Leech, R., Hindocha, C., Lawn, W., Nutt, D. J., Curran, H. V., Carhart-Harris, R. L.

Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Published
Authors
Roseman, L., Nutt, D. J., Carhart-Harris, R. L.

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression

Published
Authors
Carrillo, F., Sigman, M., Fernández Slezak, D., Ashton, M., Fitzgerald, L., Stroud, J., Nutt, D. J., Carhart-Harris, R. L.

More realistic forecasting of future life events after psilocybin for treatment-resistant depression

Published
Authors
Lyons, T., Carhart-Harris, R. L.

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Published
Authors
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., Carhart-Harris, R. L.

Your Library

Imperial College London Open-Label Psilocybin... — Clinical Trial Details | Blossom